SEARCH

SEARCH BY CITATION

  • 1
    Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311: 2933.
  • 2
    Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude GF. Sequence of MET protooncogene cDNA has features characteristic of the ty-rosine kinase family of growth-factor receptors. Proc Natl Acad Sci USA 1987; 84: 637983.
  • 3
    Ponzetto C, Giordano S, Peverali F, Delia Valle G, Abate ML, Vaula G, Comoglio PM. c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 1991; 6: 5539.
  • 4
    Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 8024.
  • 5
    Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartman G, Zarnegar R, Michalopoulos GK, Birchmeier W, Comoglio PM. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991; 10: 286778.
  • 6
    Komada M, Miyazawa K, Ishii T, Kitamura N. Characterization of hepato-cyte-growth-factor receptors on Meth A cells. Eur J Biochem 1992; 204: 85764.
  • 7
    Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995; 376: 76871.
  • 8
    Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002; 109: 8637.
  • 9
    Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, Scherer S, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim U, Feltis T, Casadevall C, Zamarron A, Bemues M, Richad S, Lips CMJ, Walther MM, Tsui L-C, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 6873.
  • 10
    Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B, Lee JY Somatic mutations in the kinase domain of the Met/ hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999; 59: 30710.
  • 11
    Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000; 19: 494753.
  • 12
    Komada M, Kitamura N. Regulatory role of major tyrosine autophosphoryla-tion site of kinase domain of c-Met receptor (scatter factor/hepatocyte growth factor receptor). J Biol Chem 1994; 269: 161316.
  • 13
    Tsukada Y, Miyazawa K, Kitamura N. High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2. J Biol Chem 2001; 276: 4096876.
  • 14
    Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 1998; 273: 1198790.
  • 15
    Ferracini R, Longati P, Naldini L, Vigna E, Comoglio PM. Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J Biol Chem 1991; 266: 1955864.
  • 16
    Naldini L, Vigna E, Ferracini R, Longati P, Gandino L, Prat M, Comoglio PM. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol 1991; 11: 1793–803.
  • 17
    Chiara F, Michieli P, Pugliese L, Comoglio PM. Mutations in the met onco-gene unveil a “dual switch” mechanism controlling tyrosine kinase activity. J Biol Chem 2003; 278: 293528.
  • 18
    Miyazawa K, Kitamura A, Naka D, Kitamura N. An alternatively processed mRNA generated from human hepatocyte growth factor gene. Eur J Biochem 1991; 197: 1522.
  • 19
    Naka D, Ishii T, Miyazawa K, Hara H, Hishida T, Kitamura N. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J Biol Chem 1992; 267: 201149.
  • 20
    Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res 2000; 60: 614859.
  • 21
    Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001; 153: 102333.
  • 22
    Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, Tamagnone L, Comoglio PM. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nature Cell Biol 2002; 4: 7204.
  • 23
    Kinoshita Y, Nakata H, Hassan S, Asahara M, Kawanami C, Matsushima Y, Naribayashi-Inomoto Y, Ping CY, Min D, Nakamura A, Chiba T. Gene expression of keratinocyte and hepatocyte growth factor during the healing of rat gastric mucosal lesions. Gastroenterology 1995; 109: 106877.
  • 24
    Schmassmann A, Stettler C, Poulsom R, Tarasova N, Hirschi C, Flogeri B, Matsumoto K, Nakamura T, Halter F. Roles of hepatocyte growth factor and its receptor Met during gastric ulcer healing in rats. Gastroenterology 1997; 113: 185872.
  • 25
    Churin Y, Al-Ghoul L, Kepp O, Meyer TF, Birchmeier W, Naumann M. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol 2003; 161: 24955.
  • 26
    Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anti-cancer drugs. Trends Mol Med 2002; 8: 1723.
  • 27
    Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreduc-tive antitumor activity in vivo. Cancer Res 2003; 63: 734555.
  • 28
    Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003; 94: 3217.